Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial
Autore:
Armstrong, WB; Kennedy, AR; Wan, XS; Taylor, TH; Nguyen, QA; Jensen, J; Thompson, W; Lagerberg, W; Meyskens, FL;
Indirizzi:
Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Otolaryngol, Orange, CA 92868 USA Univ Calif Irvine Orange CA USA 92868 t Otolaryngol, Orange, CA 92868 USA Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Med, Orange, CA 92868 USA Univ Calif Irvine Orange CA USA 92868 Ctr, Dept Med, Orange, CA 92868 USA Univ Penn, Dept Radiat Oncol, Sch Med, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104 , Sch Med, Philadelphia, PA 19104 USA Vet Affairs Med Ctr, Surg Serv, Long Beach, CA 90822 USA Vet Affairs Med Ctr Long Beach CA USA 90822 erv, Long Beach, CA 90822 USA Vet Affairs Med Ctr, Pathol Serv, Long Beach, CA 90822 USA Vet Affairs MedCtr Long Beach CA USA 90822 erv, Long Beach, CA 90822 USA Vet Affairs Med Ctr, Dent Serv, Long Beach, CA 90822 USA Vet Affairs Med Ctr Long Beach CA USA 90822 erv, Long Beach, CA 90822 USA
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 12, volume: 6, anno: 2000,
pagine: 4684 - 4691
SICI:
1078-0432(200012)6:12<4684:CMOOLA>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
RADIATION-INDUCED TRANSFORMATION; C3H-10T1/2 CELLS; MALIGNANT TRANSFORMATION; CHYMOTRYPSIN-INHIBITOR; DIETARY ADDITION; BETA-CAROTENE; MOUSE COLON; VITAMIN-A; IN-VITRO; CARCINOGENESIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Meyskens, FL Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Otolaryngol, 101 City Dr S, Orange, CA 92868 USA Univ Calif Irvine 101 City Dr S Orange CA USA 92868 92868 USA
Citazione:
W.B. Armstrong et al., "Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial", CLIN CANC R, 6(12), 2000, pp. 4684-4691

Abstract

Bowman-Birk inhibitor is a protease inhibitor derived from soybeans that has demonstrated chemopreventive activity in a number of in vitro and animalsystems, We conducted a I-month phase IIa clinical trial of Bowman-Birk inhibitor concentrate (BBIC) in patients with oral leukoplakia, BBIC was administered to 32 subjects with oral leukoplakia for 1 month. We assessed toxicity and clinical and histological response of the lesions, and oral mucosal cell protease activity (PA) and serum micronutrient levels were measured. Clinical response was determined by measurement of pre- and posttreatment individual and total lesion areas and analysis of blinded clinical judgments of photographs. On the basis of prespecified response criteria, 31% of patients achieved a clinical response (two with complete and eight with partial responses), BBIC was nontoxic in doses up to 1066 chymotrypsin inhibitory units, The mean pretreatment total lesion area decreased from 615 to 438 mm(2) after BBIC treatment (P < 0.004). A linear fit of the dose-response relationship between dose of BBIC and decrease In total lesion area was suggested (P < 0.08), and analysis of blinded clinical impression from lesion photographs confirmed this relationship (P < 0.01). Overall, at all doses tested, a 24.2% decrease in total lesion area was observed following treatment (sign rank = -142; P < 0.004), High pretreatment PA was associated with greater decreases in PA after BBIC administration (P < 0.02). BBIC demonstrated clinical activity after oral administration to patients with oral leukoplakia, These results indicate that BBIC should be investigated for chemopreventive activity in a randomized clinical trial.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 11:39:39